Advaxis (OTCMKTS:ADXS) Share Price Crosses Above 200 Day Moving Average of $0.00
Advaxis (OTCMKTS:ADXS) Share Price Crosses Above 200 Day Moving Average of $0.00
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating)'s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.00 and traded as high as $3.47. Advaxis shares last traded at $3.06, with a volume of 1,068 shares traded.
Advaxis,Inc.(OTCMKTS:ADXS-GET Rating)的股價在週一的交易中突破了200日移動均線,200日移動均線為0.00美元,最高交易價格為3.47美元。Advaxis的股票最新報3.06美元,成交量為1,068股。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, StockNews.com started coverage on shares of Advaxis in a research report on Monday, August 22nd. They issued a "sell" rating on the stock.
另外,StockNews.com在8月22日星期一的一份研究報告中開始對Advaxis的股票進行報道。他們對這隻股票發佈了“賣出”評級。
Advaxis Stock Up 0.3 %
Advaxis股價上漲0.3%
The firm has a 50-day moving average of $3.57. The stock has a market capitalization of $5.56 million, a P/E ratio of -30.60 and a beta of 2.07.
該公司的50日移動均線切入位為3.57美元。該股市值556萬美元,市盈率為-30.60,貝塔係數為2.07。
About Advaxis
關於Advaxis
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis,Inc.是一家臨牀階段的生物技術公司,專注於在美國發現、開發和商業化專有的單核細胞增生性李斯特菌(LM)技術抗原遞送產品。該公司正在開發ADXS-PSA,這是用於治療轉移性前列腺癌的第二階段臨牀試驗;ADXS-503,用於治療非小細胞肺癌;以及ADXS-504,用於治療前列腺癌。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 免費獲取StockNews.com關於Advaxis的研究報告(ADXS)
- 達頓餐廳走低通脹之路
- 這3只股票為何在9月火爆開盤
- 通貨膨脹沒有差別,但它的影響有差別
- 3只被降級的必備股票放在你的觀察名單上
- 這是對第三季度收益報告季節的預期
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Advaxis Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Advaxis和相關公司的最新新聞和分析師評級的每日簡要摘要。